340B Rebate Model – The Latest on What We Know, What We Don’t, and Efforts to Prevent It

The 340B rebate model is slated to begin on January 1 for ten drugs. With just a handful of days to go, health centers and their partners are scrambling to understand what they will need to do to access 340B pricing on critical drugs. Join Jason Reddish from the Powers team as he discusses the latest on what we know, what we still don’t know, and what efforts are being made to stop the model from moving forward. Jason will also address the financial impacts of the model and Medicare reimbursement, and how it intersects with the directive to provide insulin at 340B pricing to low-income patients.

Learning Objectives:

1. Explain the key components of the 340B rebate model, including what is currently known, what remains uncertain, and efforts to prevent the model from moving forward.
2. Assess the potential operational and financial impacts of the rebate model on health centers, including contract pharmacy challenges, potential costs, and reductions in reimbursement.
3. Identify key steps to be completed, including obtaining permission to share claims data and compliance with the requirement to provide insulin at 340B pricing to eligible low-income patients.

Audience:

• Pharmacy Managers
• Risk Managers
• Compliance Officers
• COOs
• CEOs
• CFOs
• Executive Leadership

Presenter:

• Jason Reddish